About AIGEN Sciences
AIGEN Sciences is a company based in Seoul (South Korea) founded in 2021. AIGEN Sciences has raised $8.81 million across 2 funding rounds from investors including Premier Partners, K2 Investment Partners and Medytox Venture. AIGEN Sciences offers products and services including AI Drug Discovery Platform. AIGEN Sciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Seoul, South Korea
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name (주)아이젠사이언스
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$8.81 M (USD)
in 2 rounds
-
Latest Funding Round
-
Investors
Premier Partners
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AIGEN Sciences
AIGEN Sciences offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform.
AI tool for discovering high-potency drugs with minimal toxicity.
Funding Insights of AIGEN Sciences
AIGEN Sciences has successfully raised a total of $8.81M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
-
First Round
First Round
(16 Oct 2024)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series A - AIGEN Sciences | Valuation |
investors |
|
| Oct, 2024 | Amount | Series A - AIGEN Sciences | Valuation |
investors |
Investors in AIGEN Sciences
AIGEN Sciences has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Premier Partners, K2 Investment Partners and Medytox Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity & venture capital firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
PE firm investing in South Korea and the US
|
Founded Year | Domain | Location |
Investments & Acquisitions by AIGEN Sciences
Financial Statements - AIGEN Sciences
Aigen Sciences Comparisons
Competitors of AIGEN Sciences
AIGEN Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Frequently Asked Questions about AIGEN Sciences
AIGEN Sciences was founded in 2021 and raised its 1st funding round 3 years after it was founded.
AIGEN Sciences is headquartered in Seoul, South Korea.
Jaewoo Kang is the current CEO of AIGEN Sciences.
AIGEN Sciences is a funded company, having raised a total of $8.81M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.81M, raised on Oct 16, 2024.
AIGEN Sciences was founded in 2021 in Seoul, South Korea, focusing on the biotechnology sector. A proprietary platform named AIGEN Discovery has been developed to support drug discovery processes. Features include drug targeting, data analysis, and optimization of novel compounds. The tool is utilized by researchers for advancing pharmaceutical development through AI-driven methods. Operations are centered in South Korea, with applications in global research contexts.
AIGEN Sciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
AIGEN Sciences offers AI Drug Discovery Platform.
AIGEN Sciences has 7 investors. Key investors include Premier Partners, K2 Investment Partners, Medytox Venture, Partners Investment, and QUAD Investment Management.